Study Estimating the Clinical Difference Between 300 mg and 150 mg of Secukinumab Following Dose Escalation to 300 mg in Patients With Ankylosing Spondylitis
Clinical trial NCT03350815 · COMPLETED
Trial details
- NCT number
- NCT03350815
- Sponsor
- Novartis Pharmaceuticals
- Status
- COMPLETED
- Phase
- Phase 4
- Study type
- INTERVENTIONAL
- Start date
- 2018-03-13
- Primary completion
- 2021-03-11
- Enrollment
- 322
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.